Oasmia Pharmaceutical has applied for listing on NGM Equity. The company aims
for the notation to be official in May. The purpose is to improve the
marketplace for investors and develop the conditions for the company's future
development.
Nordic Growth Market is currently processing Oasmia Pharmaceutical's
application for change of place of trade from Nordic MTF to the list NGM
Equity.
The company's purpose is to improve the conditions for trade with the company
shares, especially with regard to institutional and international investors as
well as develop the conditions for the strong development of the company that
is expected.
Day of noting and publication of the prospect and other information will be
provided during the month of April.
Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases. Oasmia develops pharmaceuticals for the future.
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase.
Oasmia is noted on NGM Nordic MTF.
More information is available at www.ngm.se or www.oasmia.com.
For further information contact info@oasmia.com or call +46 18 50 54 40.
